Disclosure: Our goal is to showcase products and services that we think you will find interesting and useful. If you buy them, Entrepreneur can get a small share of the revenue from the sale of our business partners.
When savvy investors are looking for opportunities to make their money, they are often looking to support ideas that raise eyebrows and make the average person think, wow, that’s a really smart answer to a common problem.
That’s why, when a new biotech company claims it has a product that could dramatically reduce the nearly 300,000 cases of post-surgical infections that occur in US hospitals each year, curiosity is piqued and many investors seek a way to participate. Of course, it also doesn’t hurt when the firm – Covira Surgical – is named one of Business Worldwide Magazine’s 20 Most Innovative Companies to Watch for 2021.
The Chicago-based company has generated all of this buzz by approaching the increasingly common problem of postoperative infections with an entirely new approach.
For those who work in the medical field, problems with infections that arise after surgery have become a growing problem in hospitals around the world. Regardless of the reputation of a hospital or the skill of a surgeon, infectious bacteria are a reality in every medical facility and their effects can be heartbreaking. Patients infected with a surgical site infection (SSI) are twice as likely to die, 60% more likely to be admitted to the intensive care unit, and more than five times more likely to be readmitted to hospital after their exit.
As dangerous pathogens become more virulent and resistant to antibiotics, these cases are also mainly treated with antibiotics. These drugs not only seek to attack and kill harmful bacteria, but also create collateral damage in the human body. In addition to the unpleasant side effects such as nausea, vomiting, diarrhea and bloating, antibiotics can also cause more serious problems, including, in rare cases, a drop in the number of blood cells, including white blood cells that help fight infections.
For three decades, Dr. John Alverdy has studied postoperative infections and has become a leading expert in the field. This knowledge led the surgeon at the University of Chicago Medical Center to design Covira Surgical’s flagship product, the Pi-PEG. This colorless, tasteless, antibiotic-free solution is not only formulated to be taken by patients before and after surgery, but it takes a very different approach to fighting infections than traditional antibiotics.
Rather than employing the more aggressive drug-find-and-kill tactics, Pi-PEG coats the patient’s intestinal tract and helps improve the gut microbiome, improving the body’s ability to protect itself, according to the company. In addition to enriching gut health, Pi-PEG also promotes the production of phosphates in the body, which serve as inhibitors that naturally calm the growth and spread of infectious bacteria, explains Covira.
After promoting performance in small animal trials, Covira is now leading Pi-PEG through the year-and-more long series of tests to gain U.S. Food and Drug Administration approval for testing on humans. While this approval is pending, it has not dampened enthusiasm for the treatment’s ultimate impact on the problem of infections which adds an additional $ 34 billion to health costs in the United States each year.
With profits estimated at $ 2.2 billion by 2037, Covira has also opened up opportunities for potential investors to enter the business at this early stage. Right now, those interested can check out the options through Covira’s StartEngine page and make the decision to get on board today for as little as $ 250.
The entrepreneur may receive monetary compensation from the issuer, or its agency, for making public the offer of the issuer’s securities. The entrepreneur and the issuer of this offer make no promise, representation, warranty or guarantee that any of the services will result in a profit or not result in a loss.